Amyloid and dopamine transporter imaging in mild cognitive deficit and risk for Lewy body disease


  • A large proportion of patients with mild cognitive impairment (MCI) and at least one core feature of Lewy body dementia (LBD) are characterized by low amyloid-β deposition and reduced dopamine (DA) activity.

Why this matters

  • An initial phase of LBD comprising MCI with one or more core features of LBD that may be present prior to a clinically probable LBD diagnosis has recently been formulated as the key prodromal phenotype (MCI-LB); however, the impact of the co-existing underlying pathology on clinical phenotype is unknown.

  • The association of amyloid and DA biomarkers with MCI-LB highlights the need for further longitudinal studies to investigate the trajectory of these and other biomarkers and linkage with disease progression.